High concordance of protein (by IHC), gene (by FISH; HER2 only), and microarray readout (by TargetPrint) of ER, PgR, and HER2: results from the EORTC 10041/BIG 03-04 MINDACT trial.

Publication Name: Annals of Oncology

Author(s): Viale G, Slaets L, Bogaerts J, Rutgers E, van't Veer L, Piccart-Gebhart MJ, de Snoo FA, Stork-Sloots L, Russo L, Dell'Orto P, van den Akker J, Glas A, Cardoso F; TRANSBIG Consortium & the MINDACT Investigators.

BACKGROUND: To investigate the correlation of TargetPrint with local and central immunohistochemistry/fluorescence in situ hybridization assessment of estrogen (ER), progesterone (PgR), and human epidermal growth factor receptor 2 (HER2) in the first 800 patients enrolled in the MINDACT trial. PATIENTS … Continued

European Inter-Institutional Impact Study of MammaPrint

Publication Name: The Breast

Author(s): P.G. Cusumano, D. Generali, E. Ciruelos, L. Manso, I. Ghanem, E. Lifrange, G. Jerusalem, J. Klaase, F. de Snoo, L. Stork-Sloots, L. Dekker-Vroling, M. Lutke Holzik

Aim To measure the impact of MammaPrint on adjuvant treatment decisions and to analyze the agreement in treatment decisions between hospitals from 4 European countries for the same patient cohort. Methods Breast cancer patients were prospectively enrolled and MammaPrint was … Continued

Agendia Co-Founder Awarded EU Prize for Women Innovators

Publication Name: Press Release

Laura van ‘t Veer, Ph.D., Honored as Inventor of MammaPrint Breast Cancer Test      IRVINE, CA and AMSTERDAM, March, 10, 2014 – Agendia co-founder Laura van ‘t Veer, Ph.D., has been awarded a 2014 European Union Prize for Women … Continued